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Correction: Public-Health and Individual Approaches to Antiretroviral Therapy: 
Township South Africa and Switzerland Compared
Olivia Keiser, Catherine Orrell, Matthias Egger, Robin Wood, Martin W. G. Brinkhof, Hansjakob Furrer, Gilles van Cutsem, 
Bruno Ledergerber, Andrew Boulle, for the Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to 
Evaluate AIDS in Southern Africa (IeDEA-SA)
Correction for:
Keiser O, Orrell C, Egger M, Wood R, Brinkhof MWG, et al. (2008) Public-health and individual approaches to antiretroviral 
therapy: Township South Africa and Switzerland compared. PLoS Med 5(7): e148. doi:10.1371/journal.pmed.0050148
The Table 1 originally published with this manuscript stated that 95.1% of the patients from South Africa used regimens 
recommended by guidelines, compared to 99.6% in the Swiss cohort. This is incorrect: the figures have been reversed. As the 
article text makes clear, 95.1% of the Swiss patients used regimens recommended by guidelines, compared to 99.6% in the 
South African cohorts.
A corrected version of Table 1 is published here.
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Table 1. Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV 
Cohort Study
Category Subcategory South African Cohorts Swiss HIV Cohort
Patients, n — 2,348 1,016
Females, n (%) 1,663 (71%) 333 (33%)
Age, y, median (IQR) — 32.7 (28.5–38.2) 38.3 (31.7–46.1)
CD4 cell count, cells/µl, median (IQR)  — 80 (30–138)  204 (122–291) 
CD4 cell count, number missing (%) — 123 (5.2%) 50 (4.9%)
HIV-1 viral load, log10 copies/ml, median (IQR) — 5.1 (4.6–5.5)  5.0 (4.5–5.5) 
HIV-1 viral load, number missing (%) — 288 (12.3%) 53 (5.2%)
Clinical stage: CDC stage C, WHO stage III/IV, n (%) — 2,126 (90.6%) 188 (18.5%)
Duration of follow-up (years)a, median (IQR) — 0.9 (0.5–1.5) 2.0 (1.1–2.0)
Number of patients starting HAART in year, n (%) 2001 79 (3.4%) 179 (17.6%)
2002 246 (10.5%) 204 (20.1%)
2003 509 (21.7%) 185 (18.2%)
2004–2006b 1,514 (64.5%) 448 (44.1%)
Initial HAART regimen, n (%) 2 NRTIs + 1 NNRTI 2,339 (99.7%) 470 (46.3%)
2 NRTIs + 1 PI 9 (0.4%) 449 (44.2%)
Other 0 97 (9.6%)
Four most commonly used initial HAART regimens, n (%) 3TC D4T EFV 918 (39.1%) —
3TC D4T NVP 780 (33.2%) —
3TC AZT EFV 425 (18.1%) —
3TC AZT NVP 216 (9.2%) —
3TC AZT EFV — 304 (29.9%)
3TC AZT LPV/r — 202 (19.9%)
3TC AZT NFV — 99 (9.7%)
3TC TNV EFV — 65 (6.4%)
Initial HAART regimens used to treat 95% of patients, n —4 3 6
Patients using initial HAART regimens recommended by 
guidelines, %
— 99.6 95.1
aCensored after 2 y.
bRecruitment not completed for the years 2005/06.
doi:10.1371/journal.pmed.0050195.t001